<ins id="tvjhj"></ins>
<ins id="tvjhj"><noframes id="tvjhj"><ins id="tvjhj"></ins>
<cite id="tvjhj"><th id="tvjhj"></th></cite>
<del id="tvjhj"><noframes id="tvjhj"><del id="tvjhj"></del>
<cite id="tvjhj"><noframes id="tvjhj">
<cite id="tvjhj"><noframes id="tvjhj">
<ins id="tvjhj"><noframes id="tvjhj"><ins id="tvjhj"></ins>

A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE

Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.

  • Phase 1 trials

    Phase 1 Trials

    CEMIPLIMAB*

    PD-1 Antibody
    Cancer

    REGN1979

    CD20 X CD3 Antibody
    Cancer

    CEMIPLIMAB + REGN1979

    PD-1 Antibody + CD20 X CD3 Antibody
    Cancer

    REGN3767

    LAG-3 Antibody
    Cancer

    CEMIPLIMAB + REGN3767

    PD-1 Antibody + LAG-3 Antibody
    Cancer

    REGN5458*

    BCMA X CD3 Antibody
    Cancer

    REGN4018*

    MUC16 X CD3 Antibody
    Cancer

    CEMIPLIMAB + REGN4018*

    PD-1 Antibody + MUC16 X CD3 Antibody
    Cancer

    REGN4659

    CTLA4 Antibody
    Cancer

    REGN3048-3051

    Middle Eastern Respiratory Coronavirus Antibody
    MERS-CoV infection

    POZELIMAB

    C5 Antibody
    Paroxysmal nocturnal hemoglobinuria

    REGN4461

    LEPR Antibody
    Lipodystrophy and obesity

    REGN5069

    GFRα3 Antibody
    Pain
  • Phase 2 trials

    Phase 2 Trials

    CEMIPLIMAB*

    PD-1 Antibody
    Basal cell carcinoma

    DUPILUMAB*

    IL-4R Antibody
    Grass allergy, peanut allergy

    SARILUMAB*

    IL-6R Antibody
    Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

    EVINACUMAB

    ANGPTL-3 Antibody
    Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

    REGN1908-1909

    Fel d 1 Antibody
    Cat allergy

    GARETOSMAB

    Activin A Antibody
    Fibrodysplasia Ossificans Progressiva (FOP)

    REGN3500*

    IL-33 Antibody
    Atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD)
  • Phase 3 trials

    Phase 3 Trials

    ALIROCUMAB*

    PCSK9 Antibody
    Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

    CEMIPLIMAB*

    PD-1 Antibody
    Non-small cell lung cancer, cervical cancer

    DUPILUMAB*

    IL-4R Antibody
    Atopic dermatitis in pediatrics, asthma in pediatrics, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD)

    SARILUMAB*

    IL-6R Antibody
    Polymyalgia rheumatica, giant cell arteritis

    EVINACUMAB

    ANGPTL-3 Antibody
    Homozygous familial hypercholesterolemia (HoFH)

    REGN-EB3 (REGN3470-3471-3479)

    Ebola Virus Antibody
    Ebola virus infection

    FASINUMAB?

    NGF Antibody
    Chronic pain from osteoarthritis of the knee or hip

Trials Footnotes

* in collaboration with Sanofi

? in collaboration with Teva and Mitsubishi Tanabe

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

久久日